Table 1.
Background data of 72 patients who achieved clinical response at 8 weeks of IN usage.
| Variables | UC (n = 72) |
|---|---|
| Sex (female /male) | 36/36 (50/50) |
| Age at diagnosis, years; mean (± SD) | 28.1 (± 13.9) |
| Disease duration, years; mean (± SD) | 8.28 (± 7.5) |
| pMayo before start | 6 (± 1) |
| pMayo at 8 weeks | 1 (± 1) |
| pMayo at discontinuation | 1 (± 1) |
| Extent of disease | |
| Extensive UC | 42 (58.3%) |
| Left-side UC | 27 (37.5%) |
| Proctitis | 2 (2.8%) |
| Previous therapies | |
| 5-ASA | 72 (100%) |
| Corticosteroid | 51 (72.9%) |
| Azathioprine/6-mercaptopurine | 36 (50%) |
| Anti-TNF-α inhibitor | 29 (40.3%) |
| Calcineurin inhibitor | 17 (23.6%) |
| Cytapheresis | 17 (23.6%) |
| JAK inhibitor | 6 (8.33%) |
| Anti-α4β7 integrin inhibitor | 3 (4.17%) |
| Concomitant medications when IN medication started | |
| 5-ASA | 65 (90.3%) |
| Azathioprine/6-mercaptopurine | 30 (41.7%) |
| Anti-TNF-α inhibitor | 11 (15.3%) |
| Corticosteroid | 9 (12.5%) |
| Calcineurin inhibitor | 5 (6.9%) |
| JAK inhibitor | 2 (2.8%) |
| Cytapheresis | 2 (2.8%) |
| Anti-α4β7 integrin inhibitor | 1 (1.4%) |
Data are presented as mean (± SD) and number (percentage).
IN indigo naturalis, UC ulcerative colitis, SD standard deviation, ASA aminosalicylic acid, TNF tumor necrosis factor, JAK janus kinase.